Danaher Co. (NYSE:DHR) Shares Sold by Ashford Capital Management Inc.

Ashford Capital Management Inc. reduced its position in shares of Danaher Co. (NYSE:DHR) by 14.8% in the 3rd quarter, HoldingsChannel reports. The firm owned 6,147 shares of the conglomerate’s stock after selling 1,070 shares during the period. Ashford Capital Management Inc.’s holdings in Danaher were worth $1,709,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Prestige Wealth Management Group LLC increased its holdings in shares of Danaher by 22.0% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 1,528 shares of the conglomerate’s stock valued at $425,000 after purchasing an additional 276 shares in the last quarter. Adalta Capital Management LLC grew its holdings in shares of Danaher by 52.3% in the 3rd quarter. Adalta Capital Management LLC now owns 8,467 shares of the conglomerate’s stock worth $2,356,000 after acquiring an additional 2,907 shares during the period. LRI Investments LLC increased its stake in Danaher by 82.5% in the 3rd quarter. LRI Investments LLC now owns 4,545 shares of the conglomerate’s stock valued at $1,264,000 after purchasing an additional 2,055 shares in the last quarter. Gordian Capital Singapore Pte Ltd raised its holdings in Danaher by 26.1% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 1,400 shares of the conglomerate’s stock worth $389,000 after purchasing an additional 290 shares during the last quarter. Finally, PYA Waltman Capital LLC boosted its position in Danaher by 3.0% during the third quarter. PYA Waltman Capital LLC now owns 33,368 shares of the conglomerate’s stock worth $9,277,000 after purchasing an additional 970 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 2.5 %

NYSE DHR opened at $235.91 on Tuesday. The stock has a market cap of $170.39 billion, a PE ratio of 45.02, a P/E/G ratio of 4.23 and a beta of 0.83. The business has a 50 day moving average price of $249.91 and a two-hundred day moving average price of $258.14. Danaher Co. has a fifty-two week low of $217.96 and a fifty-two week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the firm posted $2.02 EPS. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, sell-side analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Thursday, December 5th. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Barclays cut their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. UBS Group decreased their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.